Producers Online
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development…
In weeks 19 and 20 Kvika banki hf. („Kvika“ or „the bank“) purchased 14,902,447 of its own shares at the purchase price ISK 202,578,769. See further details below: DateTimeNo. of…
Í vikum 19 og 20 keypti Kvika banki hf. („Kvika“ eða „bankinn“) 14.902.447 eigin hluti að kaupverði 202.578.769 kr. eins og nánar er greint frá hér á eftir: DagsetningTímiKeyptir hlutirViðskiptaverð…
TARRYTOWN, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- via IBN – Nightfood Holdings, Inc. (OTCQB: NGTF) (“Nightfood” and the “Company”), a hospitality automation company pioneering artificial intelligence (AI)-powered robotics and…
Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at…
Cincinnati, OH, May 12, 2025 (GLOBE NEWSWIRE) -- The Tim Lamb Group is pleased to welcome Paul Gilroy to their team. Gilroy joins the Tim Lamb Group as a Director…
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in…
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de cirrhose compensée (fibrose F4) due à une MASH ;…
Die Ergebnisse stützen den potenziellen Nutzen von Efruxifermin (EFX) für eine Fibrosebesserung unter Patienten mit kompensierter Zirrhose (F4-Fibrose) aufgrund von MASH auf Basis von SYMMETRY-Studiendaten nach 96 Wochen, die auf…
SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique développant des traitements révolutionnaires pour les patients…